Bridging the gap in precision medicine: TranSYS training programme for next-generation scientists.

Introduction: In the evolving healthcare landscape, precision medicine's rise necessitates adaptable doctoral training. The European Union has recognized this and promotes the development of international, training-focused programmes called Innovative Training Networks (ITNs). In this article, we introduce TranSYS, an ITN focused on educating the next generation of precision medicine researchers.

TGF-β/SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression.

Clinical and molecular heterogeneity are hallmarks of chronic lymphocytic leukemia (CLL), a neoplasm characterized by accumulation of mature and clonal long-lived CD5 + B-lymphocytes. Mutational status of the IgHV gene of leukemic clones is a powerful prognostic tool in CLL, and it is well established that unmutated CLLs (U-CLLs) have worse evolution than mutated cases. Nevertheless, progression and treatment requirement of patients can evolve independently from the mutational status.

Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.

Activation-induced cytidine deaminase (AID) initiates somatic hypermutation and class switch recombination of the immunoglobulin genes. As a trade-off for its physiological function, AID also contributes to tumor development through its mutagenic activity. In chronic lymphocytic leukemia (CLL), AID is overexpressed in the proliferative fractions (PFs) of the malignant B lymphocytes, and its anomalous expression has been associated with a clinical poor outcome.

[The possibility of the vertical intrapartum transmission of the HIV and HB viruses].

A study was performed on 756 serum samples collected from the umbilical cord of newborn infants. HBV markers were found in 4.63% of the tested subjects.

[The virological study of a certified focus of acute respiratory diseases in a half-closed community].

An acute respiratory disease outbreak appeared during February and March 1988 in a half-closed community. Virologic investigations were conducted and an influenza virus type B strain was isolated, antigenically like B/Victoria 2/87. Administration of the anti-influenza vaccine in the fifth day of the outbreak evolution led to considerable reduction of the new cases and to outbreak extinction after 48 hours.